For the second time in as many weeks, Canadian medical cannabis producer Tilray has announced plans to exports its product overseas, this time sending its full-spectrum cannabis extracts to Germany where they will be distributed nationwide through pharmacies.
Brandon Kennedy, Tilray CEO, called the agreement “another strategic milestone” which comes on the heels of the company receiving approvals to export their products to New Zealand. Tilray has exported products to South America, Europe, and Australia since 2016.
The company is also partnering with health care and higher education institutions in Canada and Australia on cannabis therapy clinical trials. Kennedy suggested the company would also be working with researchers in Germany.
“As the world’s second largest pharmaceutical market with a population of more than 80 million people, Germany is an important market for Tilray products,” Kennedy said in a press release. “We are proud to be the first supplier to offer full-spectrum extracts to German patients throughout the country.”
The firm has partnered with German pharmaceutical wholesaler NOWEDA and service provider Paesel + Lorei on the exportation scheme, which will begin next week. NOWEDA is a cooperative owned by more than 9,000 pharmacists and currently supplies approximately 160,000 medicines and pharmacy goods. Paesel + Lorei has served the pharmaceutical sector since 1961 and a wholesaler, distributor, and logistics provider.